Compass Therapeutics (CMPX) Non-Current Assets (2019 - 2026)

Compass Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $9.5 million in Q1 2026.

• Quarterly Non-Current Assets rose 29.8% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.9 million (up 59.36% YoY) and the FY2025 annual result came in at $9.8 million, up 27.67% from the prior year.
• Non-Current Assets slipped to $9.5 million in Q1 2026 per CMPX's latest filing, from $9.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $10.5 million in Q2 2025 and troughed at $2.1 million in Q2 2024.
• A 5-year average of $6.1 million and a median of $5.7 million in 2022 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 47.17% in 2024, then jumped 408.62% in 2025.
• Over 5 years, Non-Current Assets stood at $4.9 million in 2022, then tumbled by 38.32% to $3.0 million in 2023, then surged by 155.58% to $7.7 million in 2024, then climbed by 27.67% to $9.8 million in 2025, then decreased by 2.93% to $9.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $9.5 million, $9.8 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.